Singapore markets close in 3 hours 15 minutes

GSK plc (GSK.L)

LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
Add to watchlist
1,661.00-16.80 (-1.00%)
At close: 04:41PM GMT
Full screen
Previous close1,677.80
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume8,694
Avg. volume8,427,949
Market cap67.407B
Beta (5Y monthly)0.26
PE ratio (TTM)13.84
EPS (TTM)1.20
Earnings date01 May 2024
Forward dividend & yield0.64 (3.81%)
Ex-dividend date22 Feb 2024
1y target estN/A
  • Reuters

    GSK India arm's Q3 profit falls on government price cap

    GlaxoSmithKline Pharmaceuticals, the Indian unit of the UK's GSK, reported a 3% fall in third-quarter profit on Monday, hurt by the government's pricing cap on certain medicines. GlaxoSmithKline, which derives most of its revenue from India, continued to grapple with challenges following the inclusion of its key products such as Ceftum antibiotic and T-Bact ointment in the country's National List of Essential Medicines (NLEM) in September 2022, mandating sales below a government-set price ceiling. The company, which makes Augmentin antibiotic, incurred a one-time charge of 1.63 billion rupees, related to the cost of a voluntary retirement scheme and other employee dues.

  • Insider Monkey

    30 Most Valuable Drug Companies in 2024

    In this article, we will take a look at the 30 most valuable drug companies in 2024. If you want to skip our detailed analysis of the pharmaceutical drugs market, you can go directly to 5 Most Valuable Drug Companies in 2024. The Global Pharmaceutical Drugs Market According to a report by The Business Research […]

  • GlobeNewswire

    Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

    The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globallySOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in PROGRESS-AD, the global Phase 2 clinical trial of AL101/GSK4527226 in patients with early Alzheimer’s disease (AD), including mild cognitive impairment and mild dementia due to AD. AL101 is an investigational human